Epstein Files Full PDF

CLICK HERE
Technopedia Center
PMB University Brochure
Faculty of Engineering and Computer Science
S1 Informatics S1 Information Systems S1 Information Technology S1 Computer Engineering S1 Electrical Engineering S1 Civil Engineering

faculty of Economics and Business
S1 Management S1 Accountancy

Faculty of Letters and Educational Sciences
S1 English literature S1 English language education S1 Mathematics education S1 Sports Education
teknopedia

  • Registerasi
  • Brosur UTI
  • Kip Scholarship Information
  • Performance
Flag Counter
  1. World Encyclopedia
  2. Methylphenylpiracetam - Wikipedia
Methylphenylpiracetam - Wikipedia
From Wikipedia, the free encyclopedia
(Redirected from E1R)
Methylphenylpiracetam
Names
IUPAC name
2-(5-Methyl-2-oxo-4-phenyl-pyrrolidin-1-yl)-acetamide
Identifiers
CAS Number
  • 1301211-78-8 ☒N[ChemSpider]
3D model (JSmol)
  • Interactive image
ChEMBL
  • ChEMBL2391147
ChemSpider
  • 30831670
PubChem CID
  • 52912210
CompTox Dashboard (EPA)
  • DTXSID601031901 Edit this at Wikidata
InChI
  • InChI=1S/C13H16N2O2/c1-9-11(10-5-3-2-4-6-10)7-13(17)15(9)8-12(14)16/h2-6,9,11H,7-8H2,1H3,(H2,14,16)/t9-,11-/m0/s1
    Key: ZTGRWYMPQCQTHD-ONGXEEELSA-N
SMILES
  • C[C@H]1[C@H](CC(=O)N1CC(=O)N)C2=CC=CC=C2
Properties
Chemical formula
C13H16N2O2
Molar mass 232.283 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references
Chemical compound

Methylphenylpiracetam is a derivative of piracetam and a positive allosteric modulator of the sigma-1 receptor.[1][2][3] It differs from phenylpiracetam by having a methyl group.[2]

E1R is the (4R,5S) stereoisomer of methylphenylpiracetam that has been shown to have the greatest effect on the modulation of the sigma-1 receptor.[2]

Enantiomers

[edit]

The two R-configuration enantiomers, i.e. (4R,5S) and (4R,5R), of methylphenylpiracetam are more active positive allosteric modulators of the sigma-1 receptor than the two S-configuration enantiomers, i.e. (4S,5R) and (4S,5S).[1][3]

Enantiomer σ1R PAM effect %[3]
erythro-(4R,5S) 222 ± 37
threo-(4R,5R) 191 ± 23
erythro-(4S,5R) 141 ± 40
threo-(4S,5S) 147 ± 31

Effects

[edit]

E1R enhances cognition and has efficacy against cholinergic dysfunction in mice without affecting locomotor activity.[2] Pretreatment with E1R enhanced the σ1R agonist PRE-084's stimulating effect and facilitated passive avoidance retention.[2] It alleviated scopolamine-induced cognitive impairment.[2] The cognition enhancing activity of E1R is higher than that of (R)-phenylpiracetam.[4]

Because E1R had no effect on locomotor activity, it was found to be free of potential motor side effects.[2]

Legality

[edit]

Australia

[edit]

Methylphenylpiracetam is a schedule 4 substance in Australia under the Poisons Standard (February 2020).[5] A schedule 4 substance is classified as "Prescription Only Medicine, or Prescription Animal Remedy – Substances, the use or supply of which should be by or on the order of persons permitted by State or Territory legislation to prescribe and should be available from a pharmacist on prescription."[5]

See also

[edit]
  • Diastereomer
  • List of Russian drugs

References

[edit]
  1. ^ a b Vavers E, Zvejniece L, Veinberg G, Svalbe B, Domracheva I, Vilskersts R, Dambrova M (2015). "Novel positive allosteric modulators of sigma-1 receptor". SpringerPlus. 4 (Suppl 1): P51. doi:10.1186/2193-1801-4-S1-P51. PMC 4797911. The R-configuration enantiomers of methylphenylpiracetam are more active positive allosteric modulators of Sigma-1 receptor than S-configuration enantiomers.
  2. ^ a b c d e f g Zvejniece, L; Vavers, E; Svalbe, B; Vilskersts, R; Domracheva, I; Vorona, M; Veinberg, G; Misane, I; Stonans, I; Kalvinsh, I; Dambrova, M (2014). "The cognition-enhancing activity of E1R, a novel positive allosteric modulator of sigma-1 receptors". British Journal of Pharmacology. 171 (3): 761–71. doi:10.1111/bph.12506. PMC 3969087. PMID 24490863.
  3. ^ a b c Veinberg, G; Vorona, M; Zvejniece, L; Vilskersts, R; Vavers, E; Liepinsh, E; Kazoka, H; Belyakov, S; Mishnev, A; Kuznecovs, J; Vikainis, S; Orlova, N; Lebedev, A; Ponomaryov, Y; Dambrova, M (2013). "Synthesis and biological evaluation of 2-(5-methyl-4-phenyl-2-oxopyrrolidin-1-yl)-acetamide stereoisomers as novel positive allosteric modulators of sigma-1 receptor". Bioorganic & Medicinal Chemistry. 21 (10): 2764–71. doi:10.1016/j.bmc.2013.03.016. PMID 23582449.
  4. ^ Veinberg G, Vavers E, Orlova N, Kuznecovs J, Domracheva I, Vorona M, Zvejniece L, Dambrova M (2015). "Stereochemistry of phenylpiracetam and its methyl derivative: improvement of the pharmacological profile". Chemistry of Heterocyclic Compounds. 51 (7): 601–606. doi:10.1007/s10593-015-1747-9. S2CID 93449199. In conclusion, the obtained data demonstrated that E1R is the most active memory enhancing enantiomer of the 5-methyl-substituted phenylpiracetam homolog, and its cognition enhancing activity is higher than that of (R)-phenylpiracetam.
  5. ^ a b Poisons Standard February 2020. comlaw.gov.au

External links

[edit]
  • Screening profile of 10 μM E1R in vitro binding assays (docx)

Further reading

[edit]
  • US patent 8791273, Kalvins, et al., "4R,5S-enantiomer of 2-(5-methyl-2-oxo-4-phenyl-pyrrolidin-1-yl)-acetamide with nootropic activity", issued 2014-07-29 
  • v
  • t
  • e
Sigma receptor modulators
σ1
  • Agonists: 3-PPP
  • 4-PPBP
  • 5-MeO-DMT
  • Alazocine (SKF-10047)
  • Amantadine
  • Arketamine
  • BD-737
  • BD-1052
  • Blarcamesine
  • Captodiame
  • Citalopram
  • CGRPTooltip Calcitonin gene-related peptide
  • Cloperastine
  • Cocaine
  • Cutamesine (SA-4503)
  • Cyclazocine
  • Dehydroepiandrosterone (DHEA) (prasterone)
  • Dehydroepiandrosterone sulfate (DHEA-S) (prasterone sulfate)
  • Dextrallorphan
  • Dextromethorphan (DXM)
  • Dextrorphan (DXO)
  • Dimemorfan
  • Dimethyltryptamine (DMT)
  • Ditolylguanidine (DTG)
  • Donepezil
  • Eliprodil
  • Escitalopram
  • Fabomotizole (afobazole)
  • Fluoxetine
  • Fluvoxamine
  • Ifenprodil
  • Igmesine (JO-1784)
  • IPAB
  • Ketamine
  • L-687384
  • MDMA (midomafetamine)
  • Memantine
  • Methamphetamine
  • Methoxetamine
  • Methylphenidate
  • Nepinalone
  • Neuropeptide Y
  • Noscapine
  • OPC-14523
  • Opipramol
  • Pentazocine
  • Pentoxyverine (carbetapentane)
  • PRE-084
  • Pregnenolone
  • Pregnenolone sulfate
  • Pridopidine
  • Racemethorphan (methorphan)
  • Racemorphan (morphanol)
  • UMB-23
  • UMB-82
  • Antagonists: 3-PPP
  • AC-927
  • BD-1008
  • BD-1031
  • BD-1047
  • BD-1060
  • BD-1063
  • BD-1067
  • BMY-14802 (BMS-181100)
  • CM-156
  • Dup-734
  • E-5842
  • E-52862 (S1RA)
  • Haloperidol
  • LR-132
  • LR-172
  • MS-377
  • NE-100
  • NPC-16377
  • Panamesine (EMD-57455)
  • PD-144418
  • Pentazocine
  • Progesterone
  • Rimcazole (BW-234U)
  • Sertraline
  • SR-31742A
  • Allosteric modulators: Phenytoin; Positive: Methylphenylpiracetam
  • SOMCL-668
  • Unknown/unsorted: 3-Methoxydextrallorphan
  • 3-MeO-PCP
  • 4C-T-2
  • 4-IBP
  • 4-IPBS
  • 4-MeO-PCP
  • 5-MeO-DALT
  • 5-MeO-DiPT
  • Amitriptyline
  • Azidopamil
  • Chlorpromazine
  • Clemastine
  • Clomipramine
  • Clorgiline
  • D-Deprenyl
  • DiPTTooltip N,N-Diisopropyltryptamine
  • DPTTooltip N,N-Dipropyltryptamine
  • Ibogaine
  • Imipramine
  • KCR-12-83.1
  • Nemonapride
  • Noribogaine
  • RHL-033
  • RS-67,333
  • RTI-55
  • Saffron
  • Safinamide
  • Selegiline
  • Spipethiane
  • Trifluoperazine
  • W-18
  • YKP10A
σ2
  • Agonists: 3-PPP
  • Arketamine
  • BD-1047
  • BD1063
  • Ditolylguanidine (DTG)
  • DKR-1005
  • DKR-1051
  • Haloperidol
  • Ifenprodil
  • Ketamine
  • MDMA (midomafetamine)
  • Methamphetamine
  • OPC-14523
  • Opipramol
  • PB-28
  • Phencyclidine
  • Siramesine (Lu 28-179)
  • UKH-1114
  • Antagonists: AC-927
  • BD-1008
  • BD-1067
  • CM-156
  • LR-172
  • MIN-101
  • Panamesine (EMD-57455)
  • SAS-0132
  • Zervimesine (CT-1812)
  • Unknown/unsorted: 3-Methoxydextrallorphan
  • 3-MeO-PCE
  • 4-MeO-PCP
  • 5-MeO-DALT
  • 5-MeO-DiPT
  • Clemastine
  • DiPTTooltip N,N-Diisopropyltryptamine
  • DPTTooltip N,N-Dipropyltryptamine
  • Ibogaine
  • Lu 29-252
  • Nemonapride
  • Nepinalone
  • Noribogaine
  • Pentazocine
  • RS-67,333
  • Safinamide
  • TMATooltip 3,4,5-Trimethoxyamphetamine
  • UMB-23
  • UMB-82
  • W-18
Unsorted
  • Agonists: Berberine
  • Ethylketazocine
  • Fourphit
  • Metaphit
  • Naluzotan
  • Tapentadol
  • Tenocyclidine
  • Antagonists: AHD1
  • AZ66
  • Lamotrigine
  • Naloxone
  • SM-21
  • UMB-100
  • UMB-101
  • UMB-103
  • UMB-116
  • YZ-011
  • YZ-069
  • YZ-185
  • Allosteric modulators: SKF-83959
  • Unknown/unsorted: 18-Methoxycoronaridine
  • BMY-13980
  • Butaclamol
  • Caramiphen
  • Carvotroline
  • Chlorphenamine (chlorpheniramine)
  • Chlorpromazine
  • Cinnarizine
  • Cinuperone
  • Clocapramine
  • Dezocine
  • EMD-59983
  • Hypericin (St. John's wort)
  • Fluphenazine
  • Gevotroline (WY-47384)
  • Mepyramine (pyrilamine)
  • Molindone
  • Perphenazine
  • Pimozide
  • Proadifen
  • Promethazine
  • Propranolol
  • Quinidine
  • Remoxipride
  • SL 82.0715
  • SR-31747A
  • Tiospirone (BMY-13859)
  • Venlafaxine
See also: Receptor/signaling modulators
  • v
  • t
  • e
Racetams
Racetams
  • Nootropics: Aniracetam
  • Coluracetam
  • Dimiracetam
  • Doliracetam
  • Dupracetam
  • Fasoracetam
  • Imuracetam
  • Nebracetam
  • Nefiracetam
  • Nicoracetam
  • Oxiracetam
  • Piperacetam
  • Piracetam
  • Plosaracetam
  • Pramiracetam
  • Rolipram
  • Rolziracetam
  • Anticonvulsants: Brivaracetam
  • Etiracetam
    • Levetiracetam
  • Seletracetam
Phenylpiracetams
  • Nootropics and/or stimulants: Cebaracetam
  • Methylphenylpiracetam
    • E1R ((4R,5S)-methylphenylpiracetam)
  • Phenylpiracetam (phenotropil; fonturacetam)
    • MRZ-9547 ((R)-phenylpiracetam)
    • (S)-Phenylpiracetam
  • RGPU-95 (chlorophenylpiracetam)
  • Anticonvulsants: Phenylpiracetam hydrazide
Racetam-like
  • Nootropics: Aloracetam
  • Molracetam
  • Omberacetam (Noopept)
  • Tenilsetam
  • Traneurocin (cycloprolylglycine; NA-831)
  • Anticonvulsants: Padsevonil
Retrieved from "https://teknopedia.ac.id/w/index.php?title=Methylphenylpiracetam&oldid=1328677472"
Categories:
  • Racetams
  • Receptor modulators
Hidden categories:
  • Articles without InChI source
  • Articles without KEGG source
  • Articles without UNII source
  • Articles with changed CASNo identifier
  • Articles containing unverified chemical infoboxes
  • Chembox image size set
  • Articles with short description
  • Short description matches Wikidata

  • indonesia
  • Polski
  • العربية
  • Deutsch
  • English
  • Español
  • Français
  • Italiano
  • مصرى
  • Nederlands
  • 日本語
  • Português
  • Sinugboanong Binisaya
  • Svenska
  • Українська
  • Tiếng Việt
  • Winaray
  • 中文
  • Русский
Sunting pranala
url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url
Pusat Layanan

UNIVERSITAS TEKNOKRAT INDONESIA | ASEAN's Best Private University
Jl. ZA. Pagar Alam No.9 -11, Labuhan Ratu, Kec. Kedaton, Kota Bandar Lampung, Lampung 35132
Phone: (0721) 702022
Email: pmb@teknokrat.ac.id